Search

Press release

SPHINGONY: Hair loss prevention by balancing the hair cycle, strengthening the hair follicle and improving scalp health.

Essen, December 18, 2013

The appearance of the hair is one of the first impressions of a person. With aging and under other circumstances (e.g. androgenic alopecia), hair loss occurs.

To prevent hair loss, healthy hair embedded in a healthy scalp is essential. Evonik launches SPHINGONY which will be presented at the in-cosmetics 2014 in Hamburg. This latest Hair & Scalp Care active ingredient is a naturally occurring, skin-identical sphingolipid which prevents hair loss by addressing scalp health and rebalancing the life cycle of the hair.

Various in vitro studies have shown that SPHINGONY balances the hair cycle by inhibition of 5-α-reductase, improving the scalp renewal capacity, stimulating formation of essential building blocks like proteins and ceramides and by improving scalp health by equalizing the microflora.

Extended in vivo studies have confirmed that SPHINGONY significantly prevents hair loss by prolonging the anagen growth phase of hair and effectively improves hair quality and scalp health.

Overall, SPHINGONY is a skin-identical molecule with highly scientific claim substantiation, which targets hair loss by balancing the hair cycle, strengthening the hair follicle and improving scalp health.

Linked Files

Evonik Industries SPHINONY

Evonik Industries SPHINONY

Evonik Industries SPHINONY
Contact

Janna Hullmann

Business Unit Consumer Specialties

Lisa Dierks

Manager / Personal Care

  • Company information

    Evonik, the creative industrial group from Germany, is one of the world leaders
    in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

    Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.4 billion and an operating profit (adjusted EBITDA) of about €2.4 billion (excluding Real Estate in both cases).

  • Disclaimer

    In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.